S
Scott M. Lippman
Researcher at University of California, San Diego
Publications - 676
Citations - 66362
Scott M. Lippman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 109, co-authored 651 publications receiving 60987 citations. Previous affiliations of Scott M. Lippman include Cleveland Clinic & Columbia University.
Papers
More filters
Journal ArticleDOI
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Frank V. Fossella,Scott M. Lippman,Dong M. Shin,P. Tarassoff,M. Calayag-Jung,Roman Perez-Soler,Jin Soo Lee,William K. Murphy,Bonnie S. Glisson,Edgardo Rivera,Waun Ki Hong +10 more
TL;DR: This study estimates a phase II starting dose of gemcitabine in chemotherapy-naive patients to be 2,400 mg/m2/wk for 3 consecutive weeks every 4 weeks; this is much higher than that previously reported in heavily pretreated patients.
Journal ArticleDOI
Treatment of Advanced Squamous Cell Carcinoma of the Skin with Isotretinoin
TL;DR: In-vitro findings and clinical data suggest that retinoids may be an effective and well-tolerated therapy for refractory advanced squamous cell carcinoma of the skin and the absence of any other effective systemic therapy indicates the need for continuing trials with retinoid in this disease.
Journal Article
Retinoid Receptor-dependent and -independent Effects of N-(4-Hydroxyphenyl)retinamide in F9 Embryonal Carcinoma Cells
TL;DR: Two distinct effects of 4HPR were identified in this system: a rapid induction of cell death and a slower induction of differentiation, which are likely to be receptor independent and dependent, respectively.
Journal ArticleDOI
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract.
Vali Papadimitrakopoulou,Gary L. Clayman,Dong M. Shin,Jeffrey N. Myers,Ann M. Gillenwater,Helmuth Goepfert,Adel K. El-Naggar,Jan S. Lewin,Scott M. Lippman,Waun Ki Hong +9 more
TL;DR: Biochemoprevention is a promising biologic approach for laryngeal dysplasia and needs to be investigated further.
Journal ArticleDOI
Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer
Dong M. Shin,Bonnie S. Glisson,Fadlo R. Khuri,John L. Clifford,Gary L. Clayman,Steven E. Benner,Arlene A. Forastiere,Lawrence E. Ginsberg,Diane Liu,J. Jack Lee,Jeffrey L. Myers,Helmuth Goepfert,Reuben Lotan,Waun Ki Hong,Scott M. Lippman +14 more
TL;DR: Combined 13cRA, IFNalpha, and cisplatin was clinically active in extensive locally advanced disease and each agent had independent, non-cross-resistant biologic effects in vitro, which may account for the combination's clinical activity.